Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections

Rupal M. Patel*, Larry K. Kociolek, Emily Merrick, Caroline Reuter, Kenny Kronforst, Xiaotian Zheng, Sameer J. Patel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Transitioning from administration of monthly palivizumab to a single dose at discharge was associated with substantial pharmacy cost savings. With the concurrent adoption of private hospital rooms and visitor restriction policies, hospital-wide and neonatal intensive care unit healthcare-associated respiratory syncytial virus infections decreased following these changes.

Original languageEnglish (US)
Pages (from-to)485-487
Number of pages3
JournalInfection Control and Hospital Epidemiology
Volume39
Issue number4
DOIs
StatePublished - Apr 1 2018

Funding

Financial support. Research reported in this publication was supported, in part, by the National Institutes of Health National Center for Advancing Translational Sciences (grant no. UL1TR001422).

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Epidemiology

Fingerprint

Dive into the research topics of 'Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections'. Together they form a unique fingerprint.

Cite this